Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy.
In a sample of 277 patients included in the French APROCO cohort study who were initially adherent at follow-up visit 4 months after initiation of a protease inhibitor-containing regimen, 76.4% self-reported at least one lipodystrophy-related symptom and 30.0% failed to maintain adherence behaviour 20 months after enrolment. After multiple adjustment for other related factors, such as younger age, alcohol consumption and poor housing conditions, the number of self-reported lipodystrophy symptoms was independently associated with adherence failure.
Duran
S
S
INSERM U379, Marseille, France.
Savès
M
M
Spire
B
B
Cailleton
V
V
Sobel
A
A
Carrieri
P
P
Salmon
D
D
Moatti
J P
JP
Leport
C
C
D000328:Adult; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D015331:Cohort Studies; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008060:Lipodystrophy / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D011795:Surveys and Questionnaires; D013997:Time Factors